glp-1 drugs and parkinson's disease Receptor Agonists: A New Treatment in GLP-1 Agonists: A New Frontier

Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB

Aliment Pharmacol Ther 2009;30(7):70717

Key pharma players dominate the landscape, while a wave of biosimilar and next-generation peptide developers are entering the space ahead of patent expirations

Pancreatology 16: 2-7, 2016

4 A history of gallbladder disease A 2022 systematic review of 76 randomised trials found that GLP-1 medications are associated with a relative risk of around 37% for gallbladder or biliary disease, with a higher relative risk in weight-loss trials than in diabetes trials

The industrys agility in aligning capital projects, CDMO partnerships, and tech transfer will determine whether production can keep pace with demand growth